MPC
42
-2
WDC
50
3
SO
59
6
WEC
56
3
TRV
58
2
GME
70
4
CI
55
3
PEP
50
2
DVN
16
-5
EMR
74
3
JNPR
50
4
HUM
43
-6
VNO
65
4
SPG
56
-4
AAL
57
3
WBA
54
6
HBI
55
-4
NWSA
65
2
KO
49
5
SYF
88
3
MPC
42
-2
WDC
50
3
SO
59
6
WEC
56
3
TRV
58
2
GME
70
4
CI
55
3
PEP
50
2
DVN
16
-5
EMR
74
3
JNPR
50
4
HUM
43
-6
VNO
65
4
SPG
56
-4
AAL
57
3
WBA
54
6
HBI
55
-4
NWSA
65
2
KO
49
5
SYF
88
3
Financhill
Back

Range Cancer Therapeutics ETF Stock Predictions

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
49

CNCR
Range Cancer Therapeutics ETF

Last Price:
14.00
Seasonality Move:
2.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Trade on Tuesday. Profit on Friday. Rinse & Repeat

Get the full details now.

Range Cancer Therapeutics ETF Stock Forecast

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 5.1% based on the past 9 years of stock performance.
  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%
  • Is Range Cancer Therapeutics ETF Stock Undervalued?
    The current Range Cancer Therapeutics ETF [CNCR] share price is $13.79. The Score for CNCR is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
  • CNCR is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Will Range Cancer Therapeutics ETF Stock Go Up Next Year?

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 5.1% based on the past 9 years of stock performance.

Range Cancer Therapeutics ETF Stock Rating

Sell
49
Range Cancer Therapeutics ETF (CNCR) is a Sell

Is Range Cancer Therapeutics ETF overpriced?

  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%

Range Cancer Therapeutics ETF Stock Price History

Is CNCR stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and CNCR is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Industry:
Sector:
Type:
etf
Website:

52-Week Data

52-Week High:
17.96
52-Week Low:
10.49

Prediction Charts

Market Cap:
0
Price in USD:
13.79
Volume:
5.52K
Beta:
1.11

Technical Analysis

SMA50:
14.82
SMA100:
14.78
SMA200:
15.04
52-Wk Change:
29.97%

Stock Predictions

  • Is Range Cancer Therapeutics ETF stock public?
    Yes, Range Cancer Therapeutics ETF is a publicly traded company.
  • What is the Range Cancer Therapeutics ETF stock quote today?
    The Range Cancer Therapeutics ETF stock price is 13.79 USD today.
  • How to buy Range Cancer Therapeutics ETF stock online?
    You can buy Range Cancer Therapeutics ETF shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Nov-6 15.59 15.59 15.73 15.46
Nov-7 15.73 15.80 15.91 15.73
Nov-8 15.70 15.72 15.72 15.56
Nov-11 15.94 15.74 15.94 15.59
Nov-12 15.53 15.09 15.53 15.29
Nov-13 15.34 14.80 15.34 14.94
Nov-14 14.55 14.25 14.59 14.42
Nov-15 14.25 13.39 14.25 13.45
Nov-18 13.61 13.35 13.61 13.30
Nov-19 13.20 13.43 13.51 13.20
Nov-20 13.27 13.42 13.46 13.25
Nov-21 13.32 13.22 13.41 13.09
Nov-22 13.28 13.56 13.70 13.28
Nov-25 14.00 13.79 14.03 13.92

Range Cancer Therapeutics ETF Earnings

Data Unavailable

Range Cancer Therapeutics ETF Forecast Revenue Growth

Data Unavailable

* Range Cancer Therapeutics ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.